Nexxt Spine announces US FDA clearance for Matrixx corpectomy system

3826
Nexxt Spine’s Matrixx corpectomy system

Nexxt Spine has announced US Food and Drug Administration (FDA) 510(k) clearance of the Nexxt Matrixx corpectomy system.

The Nexxt Matrixx corpectomy system has been cleared for use in the cervical spine (C2-T1) and thoracolumbar spine (T1-L5) in skeletally mature patients to replace a diseased, collapsed, damaged, or unstable vertebral body due to tumour, osteomyelitis, trauma, or for reconstruction following corpectomy performed to achieve decompression of the spinal cord and neural tissues in degenerative disorders.

The system’s interbody consists of a roughened surface and aggressive inferior/superior teeth that provide initial stabilization. Standard footprints are 12x14mm and 14x16mm with a lordosis of 0 degrees and 6 degrees and heights varying from 11–50mm available in 1mm increments.

“Here at Nexxt Spine we are committed to bringing exceptionally innovative products to the market,” says president, Andy Elsbury. “The extension of our Nexxt Matrixx line with the corpectomy system has been highly anticipated by our surgeon network, who consistently experience superior clinical outcomes. We are excited to expand this network and positively enhance the lives of more patients.”


LEAVE A REPLY

Please enter your comment!
Please enter your name here